Objective: Randomized controlled trials (RCTs) of Chinese patent medicines and classic traditional Chinese medicine prescriptions were systematically reviewed from both Chinese and English journals published in 2023. A preliminary summary and evaluation were conducted on the generation and translation of clinical evidence for these treatments. This analysis aims to inform future research on clinical efficacy evaluation and guide the rational application of evidence. Methods: RCTs of Chinese patent medicines and classic traditional Chinese prescriptions published in 2023 were comprehensively retrieved from the Artificial Intelligence Clinical Evidence Database for Chinese Patent Medicine (AICED-CPM), with supplementary searches conducted in China National Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Science and Technology Journal Database (VIP), Chinese Biomedical Literature Database (SinoMed), Cochrane Library, PubMed, Embase, and Web of Science. The study characteristics and methodological quality of these RCTs were systematically analyzed and evaluated. Results: A total of 1 443 RCTs of Chinese patent medicines were included, comprising 1 399 Chinese articles and 44 English articles. Additionally, 334 RCTs of classic traditional Chinese medicine prescriptions were found, with 331 published in Chinese and 3 in English. 196 567 participants were included, covering 585 types of Chinese patent medicines (487 oral, 61 injectable, and 37 topical) and 179 classic traditional Chinese medicine prescriptions. The involved studies encompassed 22 types of diseases, with research primarily focusing on diseases of the circulatory system, the respiratory system, and the genitourinary system. The sample sizes ranged from 18 to 3 777 participants, and most studies were conducted at a single center. Methodologically, the implementation of allocation concealment and blinding remained insufficiently emphasized. Conclusion Overall, compared with 2022, both the number of RCT publications and their methodological quality have improved in 2023, with heightened attention to research on diseases of the genitourinary system. However, quality control and standardized management in the design and implementation processes still require enhancement to produce more high-quality clinical evidence and accelerate the translation and application of this evidence.

ObjectiveTo construct an outcome set for clinical evaluation of traditional Chinese medicine （TCM） for chronic pulmonary heart disease， and to provide consensus outcomes for the evaluation of the clinical effectiveness of TCM for chronic pulmonary heart disease. MethodsWe searched randomised controlled trials of TCM for chronic pulmonary heart disease on China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform （WF）， VIP Chinese Science Journals Database （VIP）， Chinese Biomedical Literature Service Database （SinoMed）， PubMed， Cochrane Library， and Embase. We also searched Chinese Clinical Trial Registry Platform and the U.S. Clinical Trial Registry database to obtain the outcome indicators reported in the clinical research protocols of TCM for chronic pulmonary heart disease. The outcome indicators were also collected through semi-structured interviews of clinicians and patients. Then integrated the outcome indicators collected by the above methods to construct the indicator pool. Through two rounds of Delphi surveys and a consensus conference， the core outcome set for clinical evaluation of TCM for chronic pulmonary heart disease was determined. ResultsAfter screening， there were 1313 literature meeting the criteria， and 595 outcome indicators were extracted， then combined with the outcomes from semi-structured interviews which clinicians and patients concerned， finally an indicator item pool containing 369 outcome indicators were formed. After the initial screening of indicators in the pool by the steering committee， 58 indicators were established into the initial list of indicator entries. In the first round of Delphi survey， the expert coordination coefficient for the results was 0.401， and the Cronbach coefficient was 0.989. A total of 35 indicators that did not meet the criteria ［＜70% of the participants rated the outcome as 7~9 （critical） and the mean of the expert ratings ＜7］ were deleted， and 23 were retained， with 7 new indicators added that were open to supplementation by the experts， resulting in a total of 30 indicators that were included in the second round of Delphi survey. In the second round of Delphi survey， the expert coordination coefficient was 0.303， and the Cronbach coefficient was 0.974， with a total of 7 indicators that did not meet the criteria being deleted， and 21 indicators being retained for the consensus conference. After the consensus meeting， the core outcome set for clinical evaluation of chronic pulmonary heart disease in two major categories， acute exacerbation stage and stable stage， was finally determined， in which there were four indicators in acute exacerbation stage： N-terminal B-type natriuretic peptide precursor （NT-proBNP）， blood qi analysis， all-cause mortality rate， and complication rate； and there were eight indicators in the stable stage： pulmonary function index， six-minute walk test distance， New York cardiac function classification， all-cause mortality rate， re-hospitalisation rate， Chronic Obstructive Pulmonary Disease Assessment Test （CAT） score， Short Form 36 Health Survey （SF-36）， and TCM syndrome score. ConclusionThe core outcome sets of TCM clinical evaluation in the acute exacerbation stage and stable stage are constructed， which is helpful to improve the practicability， comparability and transparency of TCM clinical research results in pulmonary heart disease.

Objective To systematically evaluate and compare the efficacy and safety of different oral Chinese patent medicine combined with hormone replacement therapy(HRT)in the treatment of ovarian hypofunction related diseases.Methods Relevant randomized controlled studies on Chinese patent medicine combined with HRT for the treatment of premature ovarian insufficiency,diminished ovarian reserve,premature ovarian failure were systematically searched in CNKI,WanFang,VIP,SinoMed,PubMed,and WOS databases,and the network Meta-analysis was performed using R 4.1.0 software.Results Eighty-three randomized controlled studies were included,with 3819 cases in the control group and 3844 cases in the experimental group,involving a total of 14 Chinese patent medicine(Kuntai capsule,Peikun pill,Zuogui pill,Heche Dazao capsule,Zishen Yutai pill,Fuke Yangrong capsule,Liuwei Dihuang pill,Rentaipan tablet,Guishen pill,Huanshao capsule,Qilin pill,Tiaojing Cuyun pill,Fufang Ejiao plasma,and Zuogui pill+Ruogui pill).The results of network Meta-analysis showed that:①Lowering of follicle stimulating hormone:the top 3 in the ranking were Zishen Yutai pill,Liuwei Dihuang pill,Fuke Yangrong capsule combined with HRT.② Increasing antral follicle counting:the top 3 in the ranking were Zuogui pill,Fuke Yangrong capsule,Zuogui pill+Ruogui pill combined with HRT.③Elevating of anti-Müllerian tube hormones:the top 3 in the ranking were Rentaipan tablet,Liuwei Dihuang pill,Kuntai capsule combined with HRT.④ Lowering Kupperman's score:the top 1 in the ranking was Kuntai capsule+HRT.⑤ Increasing in overall efficiency:the top 3 in the ranking were Fufang Ejiao plasma+HRT,Guishen pill+HRT,Zishen Yutai pill+HRT.The adverse events of combined HRT with oral Chinese patent medicine were mainly gastrointestinal discomfort,dizziness and headache,breast distension and pain.Conclusion The combination of oral Chinese patent medicine with HRT can better improve ovarian function and alleviate perimenopausal symptoms.For patients with fertility requirements,priority should be given to Fuke Yangrong capsule or Liuwei Dihuang pill combined with HRT to improve FSH levels and increase follicular reserve.For patients with obvious perimenopausal symptoms,priority should be given to Kuntai capsule combined with HRT to alleviate the symptoms.And Fufang Ejiao plasma,Guishen pill,Zishen Yutai pill combined with HRT should be given to increase the overall effective rate of the treatment.

Objective To systematically evaluate and compare the efficacy and safety of different oral Chinese patent medicine combined with hormone replacement therapy(HRT)in the treatment of ovarian hypofunction related diseases.Methods Relevant randomized controlled studies on Chinese patent medicine combined with HRT for the treatment of premature ovarian insufficiency,diminished ovarian reserve,premature ovarian failure were systematically searched in CNKI,WanFang,VIP,SinoMed,PubMed,and WOS databases,and the network Meta-analysis was performed using R 4.1.0 software.Results Eighty-three randomized controlled studies were included,with 3819 cases in the control group and 3844 cases in the experimental group,involving a total of 14 Chinese patent medicine(Kuntai capsule,Peikun pill,Zuogui pill,Heche Dazao capsule,Zishen Yutai pill,Fuke Yangrong capsule,Liuwei Dihuang pill,Rentaipan tablet,Guishen pill,Huanshao capsule,Qilin pill,Tiaojing Cuyun pill,Fufang Ejiao plasma,and Zuogui pill+Ruogui pill).The results of network Meta-analysis showed that:①Lowering of follicle stimulating hormone:the top 3 in the ranking were Zishen Yutai pill,Liuwei Dihuang pill,Fuke Yangrong capsule combined with HRT.② Increasing antral follicle counting:the top 3 in the ranking were Zuogui pill,Fuke Yangrong capsule,Zuogui pill+Ruogui pill combined with HRT.③Elevating of anti-Müllerian tube hormones:the top 3 in the ranking were Rentaipan tablet,Liuwei Dihuang pill,Kuntai capsule combined with HRT.④ Lowering Kupperman's score:the top 1 in the ranking was Kuntai capsule+HRT.⑤ Increasing in overall efficiency:the top 3 in the ranking were Fufang Ejiao plasma+HRT,Guishen pill+HRT,Zishen Yutai pill+HRT.The adverse events of combined HRT with oral Chinese patent medicine were mainly gastrointestinal discomfort,dizziness and headache,breast distension and pain.Conclusion The combination of oral Chinese patent medicine with HRT can better improve ovarian function and alleviate perimenopausal symptoms.For patients with fertility requirements,priority should be given to Fuke Yangrong capsule or Liuwei Dihuang pill combined with HRT to improve FSH levels and increase follicular reserve.For patients with obvious perimenopausal symptoms,priority should be given to Kuntai capsule combined with HRT to alleviate the symptoms.And Fufang Ejiao plasma,Guishen pill,Zishen Yutai pill combined with HRT should be given to increase the overall effective rate of the treatment.

[Objective]To analyze the current situation,research characteristics and hot trends of animal experimental research on Lonicera japonica Thunb. extract,and to provide hot perspective and suggestions for future drug research and development for animal experimental research on Lonicera japonica Thunb. extract.[Methods]China National Knowledge Infrastructure(CNKI),VIP,WanFang Data,Web of Science,PubMed,Embase and SinoMed databases were searched for animal experiments related to Lonicera japonica Thunb. extract from inception to March 2024. CiteSpace and VOSviewer software were used to analyze the evidence visualization of the included literature,including the trend of publication,the cooperation of authors and institutions,keyword clustering,co-occurrence and burst word analysis,and the visualization map was drawn.[Results]A total of 1062 papers were included,and the number of published papers showed an overall upward trend,with the largest number of papers published in 2022,with a total of 139 papers,among which the author with the largest number of published studies was LI Haiqi. The research institutions mainly included traditional Chinese medicine universities and research institutes. It was found that the animal experimental research of Lonicera japonica Thunb. extract mainly focused on pharmacological effects and mechanism of action,the overall trend of current animal experimental research was to use molecular docking technology to establish a relationship with the outcome indicators of animal experiments. At present,the research hotspots are mainly liver protection and anti-inflammatory effects.[Conclusion]Animal experimental research on Lonicera japonica Thunb. extract should focus on drug efficacy,strengthen cross regional communication and cooperation between individuals and teams,and use data mining methods to deeply analyze the mechanism and laws of action of Lonicera japonica Thunb. extract.

Objective This study aims to summarize and evaluate clinical evidence of randomized controlled trial(RCT)of Chinese patent medicine published in 2021 and providing reasonable suggestions.Methods The collection literatures of Evidence Database System of TCM(EVDS)was main source,and CNKI,Wan Fang Data,VIP,SinoMed,Cochrane Library,PubMed,and EMbase databases were supplement.Obtaining the RCT of Chinese patent medicine published in 2021,and to analyze and evaluate their characteristics and methodological quality.Results 2215 RCTs of Chinese patent medicine(2206 in Chinese/9 in English)were included,which involving 237,379 patients,26 types of diseases,and 750 types of proprietary Chinese medicines(619 types of oral Chinese patent medicine,91 types of Chinese injections,and 40 types of topical Chinese patent medicine).The circulatory system diseases,respiratory system diseases and neurological diseases was highlight research area.The most number of diseases were ischemic Stroke,coronary heart disease,and angina pectoris.The sample size between 30 and 8,000 cases,and the case sources were mainly single-center.Methodologically,the implementation of allocation concealment and blinding remained unappreciated.Conclusion The number of RCTs publication increased in 2021 compared with 2020,more studies pay attention to neurological disease research,and quality control and standardized management during study design and implementation still need to be improved.

[Objective]To analyze the current situation,research characteristics and hot trends of animal experimental research on Lonicera japonica Thunb. extract,and to provide hot perspective and suggestions for future drug research and development for animal experimental research on Lonicera japonica Thunb. extract.[Methods]China National Knowledge Infrastructure(CNKI),VIP,WanFang Data,Web of Science,PubMed,Embase and SinoMed databases were searched for animal experiments related to Lonicera japonica Thunb. extract from inception to March 2024. CiteSpace and VOSviewer software were used to analyze the evidence visualization of the included literature,including the trend of publication,the cooperation of authors and institutions,keyword clustering,co-occurrence and burst word analysis,and the visualization map was drawn.[Results]A total of 1062 papers were included,and the number of published papers showed an overall upward trend,with the largest number of papers published in 2022,with a total of 139 papers,among which the author with the largest number of published studies was LI Haiqi. The research institutions mainly included traditional Chinese medicine universities and research institutes. It was found that the animal experimental research of Lonicera japonica Thunb. extract mainly focused on pharmacological effects and mechanism of action,the overall trend of current animal experimental research was to use molecular docking technology to establish a relationship with the outcome indicators of animal experiments. At present,the research hotspots are mainly liver protection and anti-inflammatory effects.[Conclusion]Animal experimental research on Lonicera japonica Thunb. extract should focus on drug efficacy,strengthen cross regional communication and cooperation between individuals and teams,and use data mining methods to deeply analyze the mechanism and laws of action of Lonicera japonica Thunb. extract.

Objective:To construct a value evaluation framework for high-value medical consumables,providing a guidance for medical insurance access and hospital access management scenarios in China.Methods:It conducted literature review,qualitative in-terviews and quantitative surveys.A total of 12 experts were invited for qualitative interviews,while 100 experts from four fields of health technology assessment,medical insurance,hospital management,and clinical practice participated in the quantitative survey.Through those process,it generated the composition of the value framework and the scoring of each item.Differences in ratings be-tween different scenarios and experts were analyzed through chi-square tests.The recommendation level for each item was graded.Re-sults:A comprehensive value evaluation framework for high-value medical consumables was established,which included 6 core dimen-sions,comprised 16 items for secondary dimensions and 50 items for tertiary dimensions.It showed significant differences between the medical insurance access and hospital access scenarios,as well as among different fields of experts in the same scenario.furthermore,grading the items in two scenarios.The medical insurance access scenario had 8 highly recommended items,and the hospital access scenario had 24 highly recommended items.Conclusion:Value evaluation should encourage multi-dimensional assessments and inter-disciplinary participation,continually improving the management of high-value medical consumables in medical insurance and hospital access.